LifeStance Health Group (LFST) Q3 FY2025 earnings: revenue $364 million, up 16.3% on the year

LifeStance Health Group, Inc. (LFST) reported revenue of $364 million for Q3 FY2025, the quarter ended 30 September 2025, up 16.3% on the same quarter a year earlier. Net income was $1 million, and diluted earnings per share $0.00. The figures are the company's own, from the 10-Q it filed with the SEC on 6 November 2025.

Revenue$364 millionup 16.3%

Net income$1 million

Diluted EPS$0.00

QuarterQ3 FY2025ended 30 September 2025

The quarter, against the one before and a year earlier

Line	Q3 FY2025	Q2 FY2025	Q3 FY2024	Change on the year
Revenue	364	345	313	+16.3%
Selling, general and administrative	95.6	97.4	85.3	+12.1%
Operating income	7.4	-3.0	0.0	+15666.0%
Operating margin	2.0%	-0.9%	0.0%
Interest expense	2.8	2.9	5.4	-48.0%
Pre-tax income	4.6	-5.9	-5.4	n/a
Income tax	3.5	-2.2	0.6	+507.8%
Effective tax rate	76.4%	n/a	n/a
Net income	1.1	-3.8	-6.0	n/a
Net margin	0.3%	-1.1%	-1.9%
Diluted EPS	$0.00	-$0.01	-$0.02	n/a

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q3 FY2025	Q2 FY2025	Q3 FY2024	Change on the year
Operating cash flow	27.3	64.4	22.7	+20.1%
Capital expenditure	10.3	7.8	5.1	+103.7%
Free cash flow	17.0	56.6	17.7	-3.8%
Free cash flow margin	4.7%	16.4%	5.7%
Cash from investing	-10.3	-7.8	-5.1	n/a
Cash from financing	-2.0	-2.0	-2.0	n/a
Depreciation and amortisation	10.3	10.6	10.4	-0.6%
Share-based compensation	18.3	21.1	14.9	+22.8%
Buybacks	n/a	0.0	n/a	n/a
Diluted shares, weighted	389m	387m	380m	+2.2%
Shares outstanding at period end	389m	389m	383m	+1.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q3 FY2025	Q2 FY2025	Q3 FY2024	Change on the year
Shareholders' equity	1,493	1,474	1,437	+3.9%
Debt	285	286	287	-1.0%
Operating lease liabilities	144	143	159	-9.1%
Other liabilities	227	243	225	+1.2%
Total liabilities and equity	2,149	2,147	2,108	+1.9%
Fixed assets	163	161	170	-4.3%
Goodwill	1,293	1,293	1,293	+0.0%
Intangible assets	181	184	195	-7.5%
Cash and equivalents	204	189	103	+98.7%
Receivables	121	129	158	-23.4%
Other assets	187	190	188	-0.7%
Total assets	2,149	2,147	2,108	+1.9%

Questions

What was LifeStance Health Group's revenue in Q3 FY2025?

LifeStance Health Group (LFST) reported revenue of $364 million for Q3 FY2025, the quarter ended 30 September 2025, up 16.3% on the same quarter a year earlier.

How much did LifeStance Health Group earn in Q3 FY2025?

Net income for Q3 FY2025 was $1 million, and diluted earnings per share $0.00.

When did LifeStance Health Group report Q3 FY2025 results?

LifeStance Health Group filed its 10-Q for the quarter ended 30 September 2025 with the SEC on 6 November 2025.

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	263	281	300	312	313	325	333	345	364	382	403	435
SG&A	131	93.4	88.9	95.2	85.3	93.7	94.4	97.4	95.6	94.8	100	108
Operating income	-74.4	-32.3	-16.8	-15.9	0.0	1.1	1.6	-3.0	7.4	18.1	22.3	30.7
Operating margin	-28%	-12%	-6%	-5%	0%	0%	0%	-1%	2%	5%	6%	7%
Interest expense	5.5	5.5	5.9	5.8	5.4	9.4	3.1	2.9	2.8	2.9	1.8	2.6
Pre-tax income	-78.0	-38.3	-20.7	-22.6	-5.4	-8.9	-1.5	-5.9	4.6	15.2	19.8	27.5
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	76%	23%	28%	14%
Net income	-61.6	-45.0	-21.1	-23.3	-6.0	-7.1	0.7	-3.8	1.1	11.7	14.2	23.6
Net margin	-23%	-16%	-7%	-7%	-2%	-2%	0%	-1%	0%	3%	4%	5%
Diluted EPS	-$0.17	-$0.12	-$0.06	-$0.06	-$0.02	-$0.01	$0.00	-$0.01	$0.00	$0.03	$0.04	$0.06
Operating cash flow	-25.4	16.8	-21.8	44.1	22.7	62.3	-3.1	64.4	27.3	57.6	33.1	99.9
Capital expenditure	9.8	11.4	5.1	5.1	5.1	6.3	7.2	7.8	10.3	10.9	10.8	12.0
Free cash flow	-35.2	5.4	-26.9	39.0	17.7	56.0	-10.3	56.6	17.0	46.6	22.3	87.9
Buybacks	n/a	n/a	n/a	n/a	n/a	n/a	0.0	0.0	n/a	n/a	49.1	48.5
Shares outstanding	379m	379m	382m	383m	383m	383m	389m	389m	389m	388m	388m	382m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2025, filed 6 November 2025, accession 0001193125-25-269712: the filing on EDGAR. All of LifeStance Health Group, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install